These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31911395)

  • 1. Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer.
    Elia EG; Städler N; Ciani O; Taylor RS; Bujkiewicz S
    Cancer Epidemiol; 2020 Feb; 64():101665. PubMed ID: 31911395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
    Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
    J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status.
    Poad H; Khan S; Wheaton L; Thomas A; Sweeting M; Bujkiewicz S
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358810
    [No Abstract]   [Full Text] [Related]  

  • 4. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
    Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
    Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer.
    Yoshida Y; Kaneko M; Narukawa M
    Int J Clin Oncol; 2020 May; 25(5):851-860. PubMed ID: 31950377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?
    Cheng S; Cheung MC; Jiang DM; McDonald E; Arciero VS; Ezeife DA; Rahmadian A; Chambers A; Sabarre KA; Parmar A; Chan KKW
    J Natl Compr Canc Netw; 2019 Dec; 17(12):1489-1496. PubMed ID: 31805528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer.
    Cooper K; Tappenden P; Cantrell A; Ennis K
    Br J Cancer; 2020 Nov; 123(11):1686-1696. PubMed ID: 32913287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual- and trial-level surrogacy in colorectal cancer.
    Buyse M; Burzykowski T; Michiels S; Carroll K
    Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
    Mushti SL; Mulkey F; Sridhara R
    Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
    [No Abstract]   [Full Text] [Related]  

  • 11. Progression-free Survival as a Surrogate End-point in Advanced Colorectal Cancer Treated with Antiangiogenic Therapies.
    Montagnani F; DI Leonardo G; Pino MS; Martella F; Perboni S; Ribecco A; Fioretto L
    Anticancer Res; 2016 Aug; 36(8):4259-65. PubMed ID: 27466541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.
    Giessen C; Laubender RP; Ankerst DP; Stintzing S; Modest DP; Mansmann U; Heinemann V
    Clin Cancer Res; 2013 Jan; 19(1):225-35. PubMed ID: 23149819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.
    Paoletti X; Oba K; Bang YJ; Bleiberg H; Boku N; Bouché O; Catalano P; Fuse N; Michiels S; Moehler M; Morita S; Ohashi Y; Ohtsu A; Roth A; Rougier P; Sakamoto J; Sargent D; Sasako M; Shitara K; Thuss-Patience P; Van Cutsem E; Burzykowski T; Buyse M;
    J Natl Cancer Inst; 2013 Nov; 105(21):1667-70. PubMed ID: 24108811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation.
    Wheaton L; Papanikos A; Thomas A; Bujkiewicz S
    Med Decis Making; 2023 Jul; 43(5):539-552. PubMed ID: 36998240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.
    Cremolini C; Antoniotti C; Pietrantonio F; Berenato R; Tampellini M; Baratelli C; Salvatore L; Marmorino F; Borelli B; Nichetti F; Bironzo P; Sonetto C; Bartolomeo MD; Braud F; Loupakis F; Falcone A; Di Maio M
    Cancer Res Treat; 2017 Jul; 49(3):834-845. PubMed ID: 27857020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.
    Michiels S; Saad ED; Buyse M
    Drugs; 2017 May; 77(7):713-719. PubMed ID: 28337673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.
    Cabibbo G; Celsa C; Enea M; Battaglia S; Rizzo GEM; Busacca A; Matranga D; Attanasio M; Reig M; Craxì A; Cammà C
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer.
    Petrelli F; Barni S
    Ann Oncol; 2013 Jan; 24(1):186-92. PubMed ID: 22898038
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.